By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Siemens Healthcare Diagnostics today announced two deals to develop companion diagnostics for candidate drugs currently in clinical trials.

One deal with ViiV Healthcare focuses on ViiV's Celsentri/Selzentry (maraviroc) AIDS therapy. The other with Tocagen is targeted at that firm's gene therapy for treating primary brain cancer.

Financial details were not disclosed for either deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.